Verity & Verity Has Upped Amgen (AMGN) Stake By $489,100; Galapagos NV Ads (GLPG) Shorts Up By 39.55%

August 9, 2017 - By Adrian Mccoy

Galapagos NV Ads (NASDAQ:GLPG) had an increase of 39.55% in short interest. GLPG’s SI was 805,900 shares in August as released by FINRA. Its up 39.55% from 577,500 shares previously. With 171,100 avg volume, 5 days are for Galapagos NV Ads (NASDAQ:GLPG)’s short sellers to cover GLPG’s short positions. The SI to Galapagos NV Ads’s float is 2.46%. The stock decreased 2.13% or $1.61 during the last trading session, reaching $73.9. About shares traded. Galapagos NV (ADR) (NASDAQ:GLPG) has risen 65.27% since August 9, 2016 and is uptrending. It has outperformed by 48.57% the S&P500.

Verity & Verity Llc increased Amgen Inc (AMGN) stake by 60.33% reported in 2016Q4 SEC filing. Verity & Verity Llc acquired 3,350 shares as Amgen Inc (AMGN)’s stock declined 9.68%. The Verity & Verity Llc holds 8,903 shares with $1.30 million value, up from 5,553 last quarter. Amgen Inc now has $126.74B valuation. The stock decreased 0.51% or $0.89 during the last trading session, reaching $173.69. About 9 shares traded. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since August 9, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.

Galapagos NV is a Belgium-based biotechnology company. The company has market cap of $3.84 billion. The Company’s activities are divided into two operating divisions: Research and Development and Services. It currently has negative earnings. The R & D division is engaged in the discovery and development of small molecules.

Among 8 analysts covering Galapagos NV (NASDAQ:GLPG), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Galapagos NV had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 18 by Goldman Sachs. The stock of Galapagos NV (ADR) (NASDAQ:GLPG) has “Neutral” rating given on Monday, September 28 by Credit Suisse. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, June 21 report. On Monday, May 2 the stock rating was maintained by Morgan Stanley with “Overweight”. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, January 5. Janney Capital upgraded the stock to “Neutral” rating in Friday, July 7 report. The rating was maintained by Cowen & Co on Friday, July 28 with “Buy”. As per Monday, January 25, the company rating was downgraded by Goldman Sachs. The stock of Galapagos NV (ADR) (NASDAQ:GLPG) earned “Hold” rating by Zacks on Tuesday, August 11. As per Friday, July 28, the company rating was maintained by Stifel Nicolaus.

Among 21 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 have Buy rating, 0 Sell and 11 Hold. Therefore 48% are positive. Amgen Inc. had 53 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The rating was maintained by UBS on Wednesday, July 26 with “Neutral”. Argus Research maintained Amgen, Inc. (NASDAQ:AMGN) on Thursday, July 27 with “Buy” rating. Gabelli initiated Amgen, Inc. (NASDAQ:AMGN) on Friday, August 26 with “Hold” rating. Oppenheimer maintained the stock with “Buy” rating in Wednesday, July 12 report. The company was upgraded on Wednesday, February 1 by Bank of America. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Buy” rating given on Monday, June 5 by Oppenheimer. BMO Capital Markets downgraded the shares of AMGN in report on Wednesday, July 26 to “Market Perform” rating. As per Thursday, July 20, the company rating was maintained by Cowen & Co. RBC Capital Markets maintained it with “Outperform” rating and $190 target in Friday, July 31 report.